UNHBy Calypso Research7 min read

UnitedHealth Group Incorporated (UNH) Q4 2025 Earnings Analysis

Unhealthy Dip as UNH Reports $113.2B and 19.6% Slump

Key Takeaways

UnitedHealth Group Incorporated (UNH) reported Q4 2025 earnings with revenue of $113.2B, representing a +12.3% year-over-year change. The stock moved -19.6% on earnings day.

The bull case: Integrated MA, OptumHealth, and OptumRx platform plus AI-driven productivity and disciplined repricing allow UNH to absorb government funding pressure and return to its 13–16% EPS growth algorithm with expanding margins.

The bear case: Persistent MA and Medicaid underfunding, structurally higher medical trends, and execution risk in OptumHealth and regulatory scrutiny on risk adjustment and PBM practices prevent a full margin recovery and keep EPS growth below historical levels.

Financial Highlights

  • Revenue: $113.2B (+12.3% YoY)
  • Gross Profit: $18.5B (16.3% margin, -4.8% YoY)
  • Operating Income: $380M (0.3% margin, -7.4% YoY)
  • Net Income: $10M
  • TTM Revenue: $447.6B

Stock Performance

  • Earnings Day Move: -19.6%
  • Year-to-Date: -16.1%
  • 1-Year Return: -38.8%
  • vs. S&P 500 (since earnings): -21.6%
  • vs. Nasdaq (since earnings): -19.7%

View live UNH data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from UnitedHealth Group Incorporated's Q4 2025 earnings call:

Sustainability of Medicare Advantage (MA) Economics and 2027 Rate Shock

Sentiment: Mixed

"Moving into 2027, the news that we received last night in the advance notice was disappointing... it will mean very meaningful benefit reductions and will once again need to take a hard look at our geographic footprint, our product footprint... and, you know, has the likelihood to play out not dissimilar to how 2026 did in terms of modifications to plan footprint and benefits." — Timothy Noel
"Given all of this and kind of where we sit, too early to talk point estimates around margin or membership for 2027. But I will say this that over the long term, given the actions that we have taken in 2026, and our integrated business model... are going to be even more important in this environment that we're being asked to operate." — Timothy Noel

OptumHealth Volatility, Turnaround Credibility, and 6–8% Margin Target

Sentiment: Mixed

"Your results in the fourth quarter and for the full year were, you know, slightly disappointing to our expectations. But really reflective of the restructuring actions that we took in the fourth quarter as well as some onetime items that are now right behind us... excluding restructuring and the move of Optum Financial, our adjusted earnings are now approximately $1.5 billion which is our new baseline that we will continue to build off of in the future." — Krista Nelson
"Another example that just gives me confidence here is we've got about 30% of our mature value based care patients that are already again inside that target margin range or above... those two examples combined with the work I described previously that we're doing to improve the consistency of of our performance just give me a lot of confidence in the runway ahead for OptumHealth." — Krista Nelson

Ability to Achieve Long-Term EPS Growth Algorithm (13–16%) Post-Disruption

Sentiment: Positive

"I can't speak to '27, but I will speak, let's say, to a longer term and that is you know, very much feel that we can be operate within our long term growth rate margins, that 13% to 16%... when you take a look at the needs in the marketplace, and the opportunity for this total enterprise to operate at its full potential." — Stephen Hemsley
"That's why I think that the long term growth rate for this enterprise and and responding to the margins or the pressures in the marketplace has actually never been better... but we have to play to full potential. And we have to execute." — Stephen Hemsley

Commercial and ACA Exchange Strategy: Margin Recovery vs. Membership Loss

Sentiment: Mixed

"On membership pertaining to the risk based decline, the largest share of that membership decline is connected to our exchange business for 2026, where we continue to expect meaningful decline between now and the end of the year... 500,000 plus attributable to the exchange business, the remainder to those three factors." — Dan Schumacher
"Our pricing posture for 2026 coming out of 2025 is going to return that market to a positive margin business for us. However, I would expect those margins in the exchange business for 2026 to be in about the 1% range. Plus or minus 1% for that business." — Dan Schumacher

Medicaid Underfunding and Margin Outlook in 2026–2027

Sentiment: Mixed

"For 2026, our view remains unchanged. In terms of overall performance. Our Medicaid business for Medicaid we do expect some margin contraction. Due to the ongoing dislocation of rates and continued elevated medical trends... we are projecting rate increases in the range of six to 7% in aggregate for the year, but that will continue to be below our medical trend." — Wayne DeVeydt
"We can continue to expect this business to see incremental pressure in 2026 largely driven by state funding shortfalls... we have received some rate relief but still anticipate the mismatch between rate and acuity to pressure performance in 2026. While we hope for further improvement in 2027." — Timothy Noel

Bull Case

Integrated MA, OptumHealth, and OptumRx platform plus AI-driven productivity and disciplined repricing allow UNH to absorb government funding pressure and return to its 13–16% EPS growth algorithm with expanding margins.

Bear Case

Persistent MA and Medicaid underfunding, structurally higher medical trends, and execution risk in OptumHealth and regulatory scrutiny on risk adjustment and PBM practices prevent a full margin recovery and keep EPS growth below historical levels.

Looking Ahead

With revenue growing +12.3% year-over-year, the key question is whether UnitedHealth Group Incorporated can sustain this growth trajectory, particularly around sustainability of Medicare Advantage (MA) Economics and 2027 Rate Shock. With operating margins at 0.3%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was UnitedHealth Group Incorporated's revenue in Q4 2025?

UnitedHealth Group Incorporated reported Q4 2025 revenue of $113.2B, representing a +12.3% year-over-year change.

Did UnitedHealth Group Incorporated beat earnings expectations in Q4 2025?

The stock declined -19.6% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Integrated MA, OptumHealth, and OptumRx platform plus AI-driven productivity and disciplined repricing allow UNH to absorb government funding pressure and return to its 13–16% EPS growth algorithm with expanding margins.

What is the bull case for UNH stock?

The bull case for UNH centers on: Integrated MA, OptumHealth, and OptumRx platform plus AI-driven productivity and disciplined repricing allow UNH to absorb government funding pressure and return to its 13–16% EPS growth algorithm with expanding margins.

What is the bear case for UNH stock?

The bear case for UNH centers on: Persistent MA and Medicaid underfunding, structurally higher medical trends, and execution risk in OptumHealth and regulatory scrutiny on risk adjustment and PBM practices prevent a full margin recovery and keep EPS growth below historical levels.

How has UNH stock performed since its Q4 2025 earnings?

UNH moved -19.6% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +21.6% since earnings. Year-to-date, the stock has returned -16.1%.

View all Healthcare Earnings Reports →

Browse all 400+ earnings reports →

Learn More

Analyze UNH in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for UnitedHealth Group Incorporated and 400+ other stocks, explore the full platform.

Open UNH on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.